Characterization of Two Monoclonal Antibodies Against the RON Tyrosine Kinase Receptor

Hybridoma ◽  
1998 ◽  
Vol 17 (6) ◽  
pp. 541-551 ◽  
Author(s):  
F.A. MONTERO-JULIAN ◽  
I. DAUNY ◽  
S. FLAVETTA ◽  
C. RONSIN ◽  
F. ANDRÉ ◽  
...  
Hybridoma ◽  
2011 ◽  
Vol 30 (4) ◽  
pp. 347-353 ◽  
Author(s):  
Tohid Kazemi ◽  
Fathollah Tahmasebi ◽  
Ali Ahmad Bayat ◽  
Neda Mohajer ◽  
Jalal Khoshnoodi ◽  
...  

1995 ◽  
Vol 57 (2) ◽  
pp. 231-236 ◽  
Author(s):  
Erika SASAKI ◽  
Yukio KANAI ◽  
Tateki CHIKAMUNE ◽  
Michiharu SAKURAI

2004 ◽  
Vol 60 (2) ◽  
pp. 127-136 ◽  
Author(s):  
Jonathan Hislop ◽  
John R. Dyer ◽  
Darcy Scott ◽  
Ronald E. van Kesteren ◽  
Wayne S. Sossin

2002 ◽  
Vol 294 (4) ◽  
pp. 813-817 ◽  
Author(s):  
Giuliana Salvatore ◽  
Satoshi Nagata ◽  
Marc Billaud ◽  
Massimo Santoro ◽  
Giancarlo Vecchio ◽  
...  

1998 ◽  
Vol 79 (01) ◽  
pp. 104-109 ◽  
Author(s):  
Osamu Takamiya

SummaryMurine monoclonal antibodies (designated hVII-B101/B1, hVIIDC2/D4 and hVII-DC6/3D8) directed against human factor VII (FVII) were prepared and characterized, with more extensive characterization of hVII-B101/B1 that did not bind reduced FVIIa. The immunoglobulin of the three monoclonal antibodies consisted of IgG1. These antibodies did not inhibit procoagulant activities of other vitamin K-dependent coagulation factors except FVII and did not cross-react with proteins in the immunoblotting test. hVII-DC2/D4 recognized the light chain after reduction of FVIIa with 2-mercaptoethanol, and hVIIDC6/3D8 the heavy chain. hVII-B101/B1 bound FVII without Ca2+, and possessed stronger affinity for FVII in the presence of Ca2+. The Kd for hVII-B101/B1 to FVII was 1.75 x 10–10 M in the presence of 5 mM CaCl2. The antibody inhibited the binding of FVII to tissue factor in the presence of Ca2+. hVII-B101/B1 also inhibited the activation of FX by the complex of FVIIa and tissue factor in the presence of Ca2+. Furthermore, immunoblotting revealed that hVII-B101/B1 reacted with non-reduced γ-carboxyglutaminic acid (Gla)-domainless-FVII and/or FVIIa. hVII-B101/B1 showed a similar pattern to that of non-reduced proteolytic fragments of FVII by trypsin with hVII-DC2/D4 on immunoblotting test. hVII-B101/B1 reacted differently with the FVII from the dysfunctional FVII variant, FVII Shinjo, which has a substitution of Gln for Arg at residue 79 in the first epidermal growth factor (1st EGF)-like domain (Takamiya O, et al. Haemosta 25, 89-97,1995) compared with normal FVII, when used as a solid phase-antibody for ELISA by the sandwich method. hVII-B101/B1 did not react with a series of short peptide sequences near position 79 in the first EGF-like domain on the solid-phase support for epitope scanning. These results suggested that the specific epitope of the antibody, hVII-B101/B1, was located in the three-dimensional structure near position 79 in the first EGF-like domain of human FVII.


Sign in / Sign up

Export Citation Format

Share Document